Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer. (April 2017)

• Record Type: Journal Article
• Authors: Franken, M.D.; van Rooijen, E.M.; May, A.M.; Koffijberg, H.; van Tinteren, H.; Mol, L.; ten Tije, A.J.; Creemers, G.J.; van der Velden, A.M.T.; Tanis, B.C.; Uyl-de Groot, C.A.; Punt, C.J.A.; Koopman, M.; van Oijen, M.G.H.
• Is Part Of: European journal of cancer. Volume 75(2017)
• Page Start: 204
• Page End: 212
• Publication Date: 2017-04
• Subjects: Colorectal -- Cancer -- Cost-effectiveness -- Capecitabine -- Bevacizumab; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/j.ejca.2017.01.019
• Languages: English
• ISSNs: 0959-8049

Abstract

Abstract: Aim: Capecitabine and bevacizumab (CAP-B) maintenance therapy has shown to be more effective compared with observation in metastatic colorectal cancer patients achieving stable disease or better after six cycles of first-line capecitabine, oxaliplatin, bevacizumab treatment in terms of progression-free survival. We evaluated the cost-effectiveness of CAP-B maintenance treatment. Methods: Decision analysis with Markov modelling to evaluate the cost-effectiveness of CAP-B maintenance compared with observation was performed based on CAIRO3 study results (n = 558). An additional analysis was performed in patients with complete or partial response. The primary outcomes were the incremental cost-effectiveness ratio (ICER) defined as the additional cost per life year (LY) and quality-adjusted life years (QALY) gained, calculated from EQ-5D questionnaires and literature and LYs gained. Univariable sensitivity analysis was performed to assess the influence of input parameters on the ICER, and a probabilistic sensitivity analysis represents uncertainty in model parameters. Results: CAP-B maintenance compared with observation resulted in 0.21 QALYs (0.18LYs) gained at a mean cost increase of €36, 845, yielding an ICER of €175, 452 per QALY (€204, 694 per LY). Varying the difference in health-related quality of life between CAP-B maintenance and observation influenced the ICER most. For patients achieving complete or partial response on capecitabine, oxaliplatin, bevacizumab induction treatment, an ICER of €149, 300 per QALY was calculated. Conclusion: CAP-B maintenance results in improved health outcomes measured in QALYs and LYs compared with observation, but also in a relevant increase in costs. Despite the fact that there is no consensus on cost-effectiveness thresholds in cancer treatment, CAP-B maintenance may not be considered cost-effective. Highlights: Compared with observation, CAP-B maintenance was associated with increased costs. CAP-B maintenance after induction treatment may not be considered cost-effective.